Dynavax sees comparable safety between Heplisav, GSK's Engerix-B

03/23/2010 | Reuters

Dynavax Technologies said safety data show no difference in terms of autoimmune adverse events between those who got its hepatitis B vaccine candidate Heplisav and GlaxoSmithKline's recently approved Engerix-B. Dynavax said the study was intended for submission to the FDA in relation to a clinical hold that was lifted in September.

View Full Article in:


Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Attest Health Care Advisors
Nationwide, SL_Nationwide
NGS Provider Enrollment Rep
National Government Services - WellPoint
Harrisburg, PA
Program Manager II
Tufts Health Plan/Network Health
Medford, MA
Director, Medicare Advantage/Medicare Part D Focus
Avalere Health
Washington, DC
Director of Clinical Research
Regenesis Biomedical, Inc.
Scottsdale, AZ